Advertisement
"The results of this study support the further clinical development ofbrostallicin. They also provide deeper insight into brostallicin's context ofvulnerability concerning different types of p53 protein, and where it is mosteffective. In our continued efforts to make cancer more treatable, resultslike these increase our understanding of cancer and potential therapies, andbring us closer to being able to offer the right drugs to the right patients,"said Jeffrey Jacob, CEO of SM.
Advertisement
This study examined brostallicin's effect on cell viability, cell cyclemodulation, and the initiation of cell death in cancer cell models with eithernormal (also referred to as wild-type) or abnormal (mutated or absent) p53tumor suppressor. These results were supported through tests in animal models,where brostallicin demonstrated a statistically significant effect onsuppressing tumor growth. To review the poster and see more detailedinformation about the study, please go tohttp://www.celltherapeutics.com/investors_news-updates.htm.
About Brostallicin
Brostallicin, a novel synthetic second-generation DNA minor groove binder,has potent cancer killing activity and has demonstrated synergism incombination with standard cytotoxic agents as well as with newer targetedtherapies in preclinical experimental tumor models. Brostallicin bindscovalently to DNA within the DNA minor groove, interfering with DNA divisionand leading to tumor cell death. More than 200 patients have been treated withbrostallicin in single-agent and combination studies. Brostallicin hadpredictable and predominantly hematologic toxicities. Activity wasdemonstrated in a number of solid tumor types. A phase II study ofbrostallicin in relapsed/refractory soft tissue sarcoma met its pre-definedactivity and safety hurdles and resulted in a first-line phase II study thatis currently being conducted by the European Organization for Research andTreatment of Cancer (EORTC).
About Systems Medicine (SM)
In July 2007, CTI acquired Systems Medicine (SM), a privately heldoncology company, in a stock-for-stock merger. SM applies a systems biologyapproach to drug development, combining pharmacogenomics and bioinformaticswith experienced preclinical, clinical, and regulatory expertise to find andexploit a specific cancer's 'context of vulnerability.' Specifically, SMdefines the molecular and genetic alterations (context) that cause cancercells to be particularly sensitive (vulnerable) to a drug or combination ofdrugs -- the 'context of vulnerability'.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed todeveloping an integrated portfolio of oncology products aimed at making cancermore treatable. For additional information, please visithttp://www.CellTherapeutics.com.
This press release includes forward-looking statements that involve anumber of risks and uncertainties, the outcome of which could materiallyand/or adversely affect actual future results. Specifically, the risks anduncertainties that could affect the development of brostallicin include risksassociated with preclinical and cli
